Literature DB >> 24423979

Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.

Peter Kamenický1, Gherardo Mazziotti, Marc Lombès, Andrea Giustina, Philippe Chanson.   

Abstract

Besides their growth-promoting properties, GH and IGF-1 regulate a broad spectrum of biological functions in several organs, including the kidney. This review focuses on the renal actions of GH and IGF-1, taking into account major advances in renal physiology and hormone biology made over the last 20 years, allowing us to move our understanding of GH/IGF-1 regulation of renal functions from a cellular to a molecular level. The main purpose of this review was to analyze how GH and IGF-1 regulate renal development, glomerular functions, and tubular handling of sodium, calcium, phosphate, and glucose. Whenever possible, the relative contributions, the nephronic topology, and the underlying molecular mechanisms of GH and IGF-1 actions were addressed. Beyond the physiological aspects of GH/IGF-1 action on the kidney, the review describes the impact of GH excess and deficiency on renal architecture and functions. It reports in particular new insights into the pathophysiological mechanism of body fluid retention and of changes in phospho-calcium metabolism in acromegaly as well as of the reciprocal changes in sodium, calcium, and phosphate homeostasis observed in GH deficiency. The second aim of this review was to analyze how the GH/IGF-1 axis contributes to major renal diseases such as diabetic nephropathy, renal failure, renal carcinoma, and polycystic renal disease. It summarizes the consequences of chronic renal failure and glucocorticoid therapy after renal transplantation on GH secretion and action and questions the interest of GH therapy in these conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24423979     DOI: 10.1210/er.2013-1071

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  48 in total

1.  Turner syndrome and autosomal dominant polycystic kidney disease.

Authors:  Rachel Styer; Matthew Stephen; Faris Hashim; Krista Birkemeier
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-11-16

2.  Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?

Authors:  Pierre Attal; Philippe Chanson
Journal:  Endocrine       Date:  2018-05-22       Impact factor: 3.633

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect.

Authors:  Andrea Giustina; Gherardo Mazziotti
Journal:  Endocrine       Date:  2014-05-06       Impact factor: 3.633

Review 5.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Effects of various stages of nephropathy on wound healing in patients with diabetes: an observational cohort study encompassing 731 diabetics.

Authors:  Paula Loewe; Ioannis Stefanidis; Peter R Mertens; Christos Chatzikyrkou
Journal:  Int Urol Nephrol       Date:  2016-02-12       Impact factor: 2.370

7.  Hematologic Markers and Prostate Cancer Risk: A Prospective Analysis in UK Biobank.

Authors:  Eleanor L Watts; Aurora Perez-Cornago; Jaimal Kothari; Naomi E Allen; Ruth C Travis; Timothy J Key
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-26       Impact factor: 4.254

8.  Characterization of an intestine-specific GH receptor knockout (IntGHRKO) mouse.

Authors:  Jonathan A Young; Elizabeth A Jensen; Austin Stevens; Silvana Duran-Ortiz; Edward O List; Darlene E Berryman; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2019-05-03       Impact factor: 2.372

Review 9.  Current best practice in the management of patients after pituitary surgery.

Authors:  Alessandro Prete; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Ther Adv Endocrinol Metab       Date:  2017-03-01       Impact factor: 3.565

10.  Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Authors:  Ludmilla Bär; Martina Feger; Abul Fajol; Lars-Oliver Klotz; Shufei Zeng; Florian Lang; Berthold Hocher; Michael Föller
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.